Jcv neutralizing antibodies
US-2015056188-A1 · Feb 26, 2015 · US
JCV neutralizing antibodies
US9567392B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9567392-B2 |
| Application number | US-201314386262-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 15, 2013 |
| Priority date | Mar 20, 2012 |
| Publication date | Feb 14, 2017 |
| Grant date | Feb 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated monoclonal antibody comprising: a heavy chain variable domain comprising a CDR1 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:31, a CDR2 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:35, and a CDR3 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:9; and a light chain variable domain comprising a CDR1 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:17, a CDR2 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:3, and a CDR3 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:4. 2. The isolated monoclonal antibody of claim 1 , wherein at least one framework region amino acid sequence of the heavy chain variable domain is at least 90% identical to at least one corresponding framework region amino acid sequence of a heavy chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:20. 3. The isolated monoclonal antibody of claim 1 , wherein the isolated monoclonal antibody comprises a heavy chain variable domain amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:20. 4. The isolated monoclonal antibody of claim 3 , wherein the isolated monoclonal antibody comprises a heavy chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:20. 5. The isolated monoclonal antibody of claim 1 , wherein at least one framework region amino acid sequence of the light chain variable domain is at least 90% identical to at least one corresponding framework region amino acid sequence of a light chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:15. 6. The isolated monoclonal antibody of claim 1 , wherein the isolated monoclonal antibody comprises a light chain variable domain amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:15. 7. The isolated monoclonal antibody of claim 6 , wherein the isolated monoclonal antibody comprises a light chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:15. 8. The isolated monoclonal antibody of claim 1 , wherein the isolated monoclonal antibody comprises a heavy chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:20 and a light chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:15. 9. The isolated monoclonal antibody of claim 1 , wherein the isolated monoclonal antibody is an isolated chimeric monoclonal antibody. 10. The isolated monoclonal antibody of claim 1 , wherein the isolated monoclonal antibody comprises an IgG1 Fc-region. 11. The isolated monoclonal antibody of claim 8 , wherein the isolated monoclonal antibody is an isolated chimeric monoclonal antibody. 12. The isolated monoclonal antibody of claim 8 , wherein the isolated monoclonal antibody comprises an IgG1 Fc-region.
Assignees
Inventors
Classifications
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
- C07K16/084Primary
Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus · CPC title
Complementarity determining region [CDR] · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Framework region [FR] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9567392B2 cover?
- In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid bind…
- Who is the assignee on this patent?
- Biogen Ma Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/084. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).